[
    [
        {
            "time": "",
            "original_text": "快讯 | 华东医药参投 Ashvattha B轮融资，获得8款产品在20个亚洲国家和地区的独家许可",
            "features": {
                "keywords": [
                    "华东医药",
                    "Ashvattha",
                    "B轮融资",
                    "独家许可",
                    "亚洲市场"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "快讯 | 华东医药参投 Ashvattha B轮融资，获得8款产品在20个亚洲国家和地区的独家许可",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        }
    ]
]